placeholder image
J. P. Abeykoon All authors
About
Publications While At HealthPartners
Highlights
selected publications
Journal Article
  • Efficacy of MEK inhibitors in Erdheim-Chester disease: impact of MAPK pathway pathogenic variants. 
    Leukemia. 2025
  • PD-L1 expression and response to immune checkpoint inhibitor therapy in malignant histiocytic neoplasms. 
    Leukemia and Lymphoma. 2025
  • Low magnesium levels and prognosis in newly diagnosed diffuse large B-cell lymphoma. 
    The oncologist. 2024
  • Monocyte response to SARS-CoV-2 protein ORF8 is associated with severe COVID-19 infection in patients with chronic lymphocytic leukemia. 
    Haematologica. 2024
  • Personalized medicine in histiocytic disorders: novel targets in patients without MAPK alterations. 
    JCO precision oncology. 2024
    • Contact
    full name
  • J. P. Abeykoon
    • Quick Info
    Publications
    Publications in the past 10 years based solely on publications while at HealthPartners. Publications in prior years appear in grey.
    Collaboration